Core Viewpoint - The company has developed a "Quality Improvement, Efficiency Enhancement, and Return to Shareholders" action plan for 2025, aimed at enhancing operational quality and efficiency while safeguarding investor rights and promoting sustainable development [1][12]. Group 1: Business Focus and Core Competitiveness - The company focuses on cell and gene therapy technology services, providing CRO services for basic research and CDMO services for drug development [1][2]. - The company aims to ensure steady growth in its existing CRO business while exploring new business opportunities and technologies to enhance profitability [2][3]. - In the CDMO sector, the company plans to leverage its production capacity and technical advantages to support clinical projects and attract more orders [3][4]. Group 2: Investor Returns and Shareholder Rights - The company emphasizes investor returns and has decided not to distribute dividends for 2024 due to operating losses, prioritizing financial stability and long-term shareholder interests [8][9]. - A share buyback plan will be implemented to enhance shareholder value and market recognition [9][10]. Group 3: Information Disclosure and Investor Communication - The company prioritizes high-quality information disclosure and has established multiple channels for investor communication, including performance briefings and online platforms [10][11]. - Efforts will be made to improve transparency and respond to market concerns, ensuring investors are well-informed about the company's operations and strategies [11][12]. Group 4: Governance and Sustainable Development - The company is committed to enhancing its governance structure and compliance with legal regulations, focusing on sustainable development and ESG initiatives [11][12]. - A robust governance framework will be maintained to ensure effective oversight and decision-making, benefiting both the company and its shareholders [12][13].

在细胞和基因治疗 CRO 业务领域，①确保现有优势业务的稳健增长的同时， 重点跟进自主研发成果的应用以及引进创新产品的落地，加强组学等新业务的产 能建设和市场推广，以满足客户多样化研究需求，不断扩大客户群体；②以工具 病毒载体制备服务、细胞株制备服务为突破点，积极开拓海外科研服务市场，提 升品牌知名度，为 CRO 业务长期发展奠定市场基础；③不断挖掘 CRO 客户早研阶 段的新药管线或创新技术转化需求，为 CDMO 业务导入寻找更多合作机遇，同时 推动基础研究成果转化，提升 CRO 服务价值。 1 一、聚焦主营业务，提升核心竞争力 公司聚焦并深耕细胞和基因治疗技术服务领域多年，专注于为细胞和基因治 疗的基础研究提供基因治疗载体研制、基因功能研究、药物靶点及药效研究等 CRO 服务；为细胞和基因治疗药物的研发提供工艺开发及测试、IND-CMC 药学研 究、临床样品及商业化产品的 GMP 生产等 CDMO 服务；为再生医学及抗衰领域提 供细胞制备、重组蛋白/外泌体等细胞衍生物生产、细胞存储等技术服务。 近两年来受到创新药行业整体发展波折的影响，公司 CDMO 业务业绩出现亏 损；面对国内生物医药领域面临的新挑战， ...

Group 1 - The core viewpoint of the news is that He Yuan Bio is experiencing a decline in stock price and financial performance, indicating potential challenges in the biotechnology sector focused on gene therapy [1] - As of the first quarter of 2025, He Yuan Bio reported a revenue of 52.84 million yuan, a year-on-year decrease of 11.29%, and a net loss of approximately 59.48 million yuan, reflecting a year-on-year decline of 41.04% [1] - The company's gross profit margin is reported at -36.44%, indicating significant financial strain [1] Group 2 - He Yuan Bio's current market capitalization is approximately 3.881 billion yuan, with a price-to-earnings (PE) ratio of -11.45 [2] - The company has a price-to-book (PB) ratio of 2.39, which is higher than the industry average of 2.64 [2] - The biotechnology industry average PE ratio is 38.04, while the median is 42.05, suggesting that He Yuan Bio is underperforming compared to its peers [2]

证券代码：688238 证券简称：和元生物 公告编号：2025-038 和元生物技术（上海）股份有限公司 关于变更持续督导保荐代表人的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 和元生物技术（上海）股份有限公司（以下简称"公司"）于近日收到公司 首次公开发行股票并在上海证券交易所科创板上市（以下简称"首发项目"）的 保荐机构国泰海通证券股份有限公司（原名为"海通证券股份有限公司"，以下 简称"国泰海通证券"、"保荐机构"）出具的《国泰海通证券股份有限公司关 于更换和元生物技术（上海）股份有限公司持续督导保荐代表人的函》。 国泰海通证券原委派陈恒瑞先生、张子慧先生为公司首发项目的保荐代表 人，负责保荐工作及持续督导工作，持续督导期至 2025 年 12 月 31 日。因原保 荐代表人张子慧先生工作发生变动，无法继续从事对公司的持续督导工作，为保 证持续督导工作的有序进行，国泰海通证券委派保荐代表人王莉女士（简历详见 附件）接替张子慧先生的工作，继续履行对公司持续督导保荐责任。 本次保荐代表人变更后，公司首发项目的持 ...

Group 1 - Shengxiang Bio plans to increase its investment in Hunan Shengwei Kunteng Biotechnology Co., Ltd. by 100 million yuan to enhance its industrial chain layout in the POCT field, resulting in a 44.6441% stake in Shengwei Kunteng after the investment [1] - Yaguang Technology's subsidiary Chengdu Yaguang signed a product pre-production agreement worth 101 million yuan, accounting for 10.56% of the company's audited revenue for the last fiscal year [1] Group 2 - Chutianlong's shareholder plans to reduce its stake by up to 3%, equating to 13.83 million shares, due to personal funding needs [2] - Naipu Mining intends to invest up to 45 million USD in Swiss Veritas Resources AG, acquiring a 22.5% stake to extend its industrial chain [2][3] Group 3 - Diri Medical's shareholder plans to reduce its stake by up to 3%, totaling 814.83 thousand shares, due to funding needs [4] - Kangtai Medical's controlling shareholder plans to reduce its stake by up to 2.99%, equating to 12 million shares [5] Group 4 - Iwu Bio's controlling shareholder plans to transfer up to 450 thousand shares through block trading, representing 0.86% of the total share capital [7] - Guokai Hengtai's four shareholders plan to collectively reduce their stake by up to 4.7%, totaling 22.94 million shares [9] Group 5 - *ST Zhongcheng submitted a hearing application to the Shenzhen Stock Exchange in response to a delisting notice [10] - Donghua Software's actual controller and associated parties plan to reduce their stake by up to 1%, totaling 32.05 million shares [12] Group 6 - Shandong Molong's shareholder reduced its H-share holdings by 107 million shares, representing 13.39% of the total share capital [12] - Yinbang Co.'s shareholder plans to reduce its stake by up to 1%, totaling 821.92 thousand shares [13] Group 7 - Jinxinnong reported April sales of 10.65 million pigs, generating sales revenue of 139 million yuan, with an average selling price of 15.05 yuan per kilogram [14] - Dongfang Jiasheng purchased 9.54 million shares of Zhonggu Logistics for approximately 99.72 million yuan, representing 4.18% of the company's net assets [15] Group 8 - Linglong Tire's controlling shareholder received a financing commitment of up to 270 million yuan for stock repurchase [16] - Wuchan Jinlun's shareholder plans to reduce its stake by up to 3%, totaling 619.77 thousand shares [18] Group 9 - Pengyao Environmental's directors and executives plan to collectively reduce their stake by up to 0.07% [19] - Ruihu Mould's controlling shareholder plans to reduce its stake by up to 1.92%, totaling 401.89 thousand shares [20] Group 10 - Electric Alloy's shareholder plans to reduce its stake by up to 0.63%, totaling 210.88 thousand shares [22] - Shanghai Xinyang's controlling shareholder plans to reduce its stake by up to 0.64%, totaling 200 thousand shares [24] Group 11 - Sujiao Ke's controlling shareholder plans to acquire up to 2% of the company's shares from a fund [26] - Heyuan Bio's shareholders plan to reduce their stake by up to 1%, totaling 649.04 thousand shares [27]

中国经济网北京5月9日讯和元生物(688238.SH)昨日晚间发布公告称，近日，公司收到股东股东浙江华睿盛银创业投资有限公司(以下 简称"华睿盛银")及其一致行动人出具的《关于股东减持计划的告知函》。 公司股东华睿盛银及其一致行动人拟通过集中竞价、大宗交易的方式减持所持公司股份，减持股份数量合计不超过6,490,367股，占 公司总股本比例不超过1%。上述减持自公告披露之日起15个交易日后的3个月内进行。 其中，华睿盛银计划减持数量不超过1,100,000股，计划减持比例不超过0.1695%；诸暨富华产业转型升级基金合伙企业(有限合伙)(以 下简称"诸暨富华")计划减持数量不超过1,000,000股，计划减持比例不超过0.1541%；浙江华睿胡庆余堂健康产业投资基金合伙企业 (有限合伙)(以下简称"华睿胡庆余堂")计划减持数量不超过1,000,000股，计划减持比例不超过0.1541%；浙江华睿火炬创业投资合伙 企业(有限合伙)(以下简称"华睿火炬")计划减持数量不超过1,910,275股，计划减持比例不超过0.2943%；杭州华睿嘉银股权投资合伙 企业(有限合伙)(以下简称"华睿嘉银")计划减持数量不超过1 ...

证券代码：688238 证券简称：和元生物 公告编号：2025-037 和元生物技术（上海）股份有限公司 股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 大股东持股的基本情况 截至本公告披露日，和元生物技术(上海)股份有限公司(以下简称"公司") 股东浙江华睿盛银创业投资有限公司（以下简称"华睿盛银"）持有公司股份 19,672,145 股，占公司总股本的比例为 3.0310%；诸暨富华产业转型升级基金合 伙企业（有限合伙）（以下简称"诸暨富华"）持有公司股份 7,052,900 股，占 公司总股本的比例为 1.0867%；浙江华睿胡庆余堂健康产业投资基金合伙企业 （有限合伙）（以下简称"华睿胡庆余堂"）持有公司股份 4,614,693 股，占公 司总股本的比例为 0.7110%；浙江华睿火炬创业投资合伙企业（有限合伙）（以 下简称"华睿火炬"）持有公司股份 3,916,087 股，占公司总股本的比例为 0.6034%；杭州华睿嘉银股权投资合伙企业（有限合伙）（以下简称"华 ...

Jin Mao Law Firm 金 茂 律 師 事 務 所 40th Floor Rund Center 222 East Van An Road, Shanghai 200002, PR 海市延安东路 227 号外滩中 Tel/电话:(8621) 6249 6040 Fax/传真:(8621) 6248 2266 Website/网址: www.jinmao.com.cn 上海市金茂律师事务所 关于和元生物技术(上海)股份有限公司 2024年年度股东大会之法律意见书 致:和元生物技术(上海)股份有限公司 和元生物技术(上海)股份有限公司(以下简称"公司")2024年年度股东大 会(以下简称"本次股东大会")于 2025年5月8日下午在公司会议室召开。上 海市金茂律师事务所(以下简称"本所")经公司聘请并接受公司委托,委派马也 律师、赵可沁律师(以下简称"本所律师")出席本次股东大会,并根据《中华人 民共和国公司法》(以下简称"《公司法》")、《中华人民共和国证券法》(以 下简称"《证券法》")、中国证券监督管理委员会公布的《上市公司股东会规则》 (以下简称"《股东会规则》")等相关法律、法规和规范性文件以 ...

证券代码：688238 证券简称：和元生物 公告编号：2025-036 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 | 1、出席会议的股东和代理人人数 | 100 | | --- | --- | | 普通股股东人数 | 100 | | 2、出席会议的股东所持有的表决权数量 | 176,805,041 | | 普通股股东所持有表决权数量 | 176,805,041 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 28.0505 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 28.0505 | （四） 表决方式是否符合《公司法》及公司章程的规定，大会主持情况等。 本次股东大会由公司董事会召集，董事长潘讴东先生主持，采用现场表决与 （一） 股东大会召开的时间：2025 年 5 月 8 日 （二） 股东大会召开的地点：上海市临港新片区沧海路 3888 号 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： 和元生物技 ...

和元生物公告，股东华睿盛银及其一致行动人计划减持不超过649.04万股，占公司总股本的1%。减持 期间为2025年5月30日至2025年8月29日，减持方式为集中竞价和大宗交易。 ...